Trial reportPloS one2026
Patients' perceptions of care in a Type 1 hybrid effectiveness-implementation trial on intravenous iron for anaemia in pregnancy in Nigeria.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing parenteral therapy for anaemia among pregnant women in rural India.Public health action · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIron deficiency anaemia is a common cause of anaemia in pregnancy, which is highly prevalent in low-and middle-income countries (LMICs). Evidence from LMICs indicates that intravenous (IV) iron formulations such as ferric carboxymaltose (FCM) are safe and effective alternatives to oral iron, and there is emerging data on implementation strategies and outcomes. Client outcomes are important additional considerations for successful scale-up of new interventions. We assessed patient experiences and satisfaction among women receiving IV versus oral iron for anaemia in pregnancy in Nigeria.
methodsThis mixed-methods study was nested in a type 1 hybrid effectiveness-implementation trial that enrolled 1,056 pregnant women at 20-32 weeks gestational age. Participants were randomised to receive either FCM or oral ferrous sulphate (FS). Twenty-five percent of participants were sequentially sampled for interviewer-administered exit surveys and 66 women who received IV iron were purposively selected for in-depth interviews at last study visit. Quantitative data from the two treatment groups were evaluated using the Chi-squared test, while qualitative data were analysed thematically.
resultsWe surveyed 252 women (128 treated with FCM and 124 with FS). Significantly higher proportions of the FCM (73.4%) versus FS group (57.3%) had positive perceptions of care (p = 0.007). Positive perceptions, experiences and satisfaction with FCM were buttressed by the qualitative findings, for reasons such as good communication and quality of provider care, single-dose administration, minimal side effects, positive health outcomes and not bearing treatment costs.
conclusionParticipants in this IV versus oral iron trial had positive perceptions of FCM. These patient-reported findings support available evidence on service and implementation outcomes and further support IV iron scale up in LMIC settings. Future implementation research should further assess client outcomes under real-world conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.